Nursing Elites

1. A client is starting therapy with bicalutamide. Which of the following adverse effects should the nurse instruct the client to monitor?

• A. Muscle pain
• B. Flushing
• C. Gynecomastia
• D. Hyperglycemia

Correct answer: C

Rationale: The correct answer is gynecomastia (Choice C). Bicalutamide is associated with gynecomastia due to its antiandrogenic properties. Gynecomastia, the development of breast tissue in males, is an important adverse effect to monitor when taking bicalutamide. Choices A, B, and D are incorrect. Muscle pain and flushing are not commonly associated with bicalutamide use. Hyperglycemia is not a typical adverse effect of bicalutamide therapy.

2. What information should you provide to your patient if they are taking sennosides? Select All That Apply.

• A. Sennosides should be used for short-term therapy
• B. The medication does not cure hypothyroidism
• C. The color of the urine may change to pink, red, violet, yellow, or brown
• D. Make sure to use other forms of bowel regulation

Correct answer: A

Rationale: When educating a patient taking sennosides, it is important to emphasize that these laxatives should be used for short-term therapy only. The medication does not address hypothyroidism, so this information is not relevant. Patients should be informed that the color of their urine may change to various colors like pink, red, violet, yellow, or brown, which is a common side effect of sennosides. It is advisable to incorporate other forms of bowel regulation alongside sennosides for optimal bowel health. Choice A is correct as it provides essential guidance on the duration of sennosides use. Choice B is incorrect because sennosides are not used to cure hypothyroidism. Choice C is correct as it highlights a common side effect of sennosides. Choice D is incorrect because it does not specifically relate to sennosides but rather suggests using other forms of bowel regulation in general.

3. A client with chronic renal disease is receiving therapy with epoetin alfa. Which of the following laboratory results should the nurse review for an indication of a therapeutic effect of the medication?

• A. The leukocyte count
• B. The platelet count
• C. The hematocrit (Hct)
• D. The erythrocyte sedimentation rate (ESR)

Correct answer: C

Rationale: The correct answer is C: The hematocrit (Hct). Monitoring the hematocrit is essential to assess the therapeutic effect of epoetin alfa because this medication stimulates red blood cell production in clients with chronic renal disease. The leukocyte count (choice A) and platelet count (choice B) are not directly affected by epoetin alfa therapy. The erythrocyte sedimentation rate (ESR) (choice D) is a non-specific marker of inflammation and is not used to monitor the therapeutic effect of epoetin alfa.

4. A client has a new prescription for Captopril to treat hypertension. Which of the following instructions should the nurse include?

• A. Take the medication with food.
• B. Avoid salt substitutes.
• C. Increase your intake of potassium-rich foods.
• D. Expect a dry cough to develop.

Correct answer: B

Rationale: The correct instruction for the nurse to include is to advise the client to avoid salt substitutes. Salt substitutes often contain potassium, and captopril can cause hyperkalemia. By avoiding salt substitutes, the client can prevent elevated potassium levels and associated complications.

5. A client has a new prescription for Losartan. Which of the following laboratory values should the nurse monitor?

• A. Serum potassium
• B. Serum sodium
• C. Serum calcium
• D. Serum magnesium

Correct answer: A

Rationale: Corrected Rationale: Losartan, an angiotensin II receptor blocker (ARB), can cause hyperkalemia by affecting the renin-angiotensin-aldosterone system. Monitoring serum potassium levels is crucial to detect and manage any potential hyperkalemia, which can lead to serious cardiac arrhythmias. Monitoring serum sodium, calcium, or magnesium levels is not typically required when a patient is on Losartan unless there are specific indications or comorbidities that warrant such monitoring.

Similar Questions